» Articles » PMID: 29789416

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2018 May 24
PMID 29789416
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumor microenvironment that suppresses and excludes cytotoxic CD8 T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not completely understood. In this study, we find that macrophage-derived granulin contributes to cytotoxic CD8 T-cell exclusion in metastatic livers. Granulin expression by macrophages was induced in response to colony-stimulating factor 1. Genetic depletion of granulin reduced the formation of a fibrotic stroma, thereby allowing T-cell entry at the metastatic site. Although metastatic PDAC tumors are largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin-depleted tumors restored the antitumor immune defense and dramatically decreased metastatic tumor burden. These findings suggest that targeting granulin may serve as a potential therapeutic strategy to restore CD8 T-cell infiltration in metastatic PDAC, thereby converting PDAC metastatic tumors, which are refractory to immune checkpoint inhibitors, into tumors that respond to immune checkpoint inhibition therapies. These findings uncover a mechanism by which metastatic PDAC tumors evade the immune response and provide the rationale for targeting granulin in combination with immune checkpoint inhibitors for the treatment of metastatic PDAC. http://cancerres.aacrjournals.org/content/canres/78/15/4253/F1.large.jpg .

Citing Articles

A stumbling block in pancreatic cancer treatment: drug resistance signaling networks.

Liu J, Zhang B, Huang B, Zhang K, Guo F, Wang Z Front Cell Dev Biol. 2025; 12:1462808.

PMID: 39872846 PMC: 11770040. DOI: 10.3389/fcell.2024.1462808.


Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif M Nat Commun. 2025; 16(1):335.

PMID: 39762215 PMC: 11704331. DOI: 10.1038/s41467-024-55330-7.


Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy.

Wang Q, Wang J, Xu K, Luo Z Front Immunol. 2024; 15:1481247.

PMID: 39416792 PMC: 11479911. DOI: 10.3389/fimmu.2024.1481247.


Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease.

Bai Y, Chi K, Zhao D, Shen W, Liu R, Hao J J Transl Int Med. 2024; 12(4):395-405.

PMID: 39360161 PMC: 11444470. DOI: 10.2478/jtim-2023-0130.


Single-cell RNA sequencing highlights the immunosuppression of IDO1 macrophages in the malignant transformation of oral leukoplakia.

Zhang Y, Zhang J, Zhao S, Xu Y, Huang Y, Liu S Theranostics. 2024; 14(12):4787-4805.

PMID: 39239507 PMC: 11373622. DOI: 10.7150/thno.99112.


References
1.
Strachan D, Ruffell B, Oei Y, Bissell M, Coussens L, Pryer N . CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology. 2014; 2(12):e26968. PMC: 3902121. DOI: 10.4161/onci.26968. View

2.
Jiang H, Hegde S, Knolhoff B, Zhu Y, Herndon J, Meyer M . Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22(8):851-60. PMC: 4935930. DOI: 10.1038/nm.4123. View

3.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

4.
Anderson K, Stromnes I, Greenberg P . Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017; 31(3):311-325. PMC: 5423788. DOI: 10.1016/j.ccell.2017.02.008. View

5.
Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View